Cargando…
Hepatic Venous Occlusion Type of Budd–Chiari Syndrome versus Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstructive Syndrome: A Multi-Center Retrospective Study
(1) Background: Hepatic venous occlusion type of Budd–Chiari syndrome (BCS-HV) and pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome (PA-HSOS), share similar clinical features, and imaging findings, leading to misdiagnoses; (2) Methods: We retrospectively analyzed 139 patients w...
Autores principales: | Tong, Yaru, Zhang, Ming, Qi, Zexue, Wu, Wei, Chen, Jinjun, He, Fuliang, Han, Hao, Ding, Pengxu, Wang, Guangchuan, Zhuge, Yuzheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143067/ https://www.ncbi.nlm.nih.gov/pubmed/37108988 http://dx.doi.org/10.3390/jpm13040603 |
Ejemplares similares
-
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
por: Zhang, Wei, et al.
Publicado: (2021) -
Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China
por: Shang, Haitao, et al.
Publicado: (2021) -
Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wang, Xuan, et al.
Publicado: (2022) -
Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Gynura japonica Containing Pyrrolizidine Alkaloids
por: Wang, Xunjiang, et al.
Publicado: (2021) -
Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome with diffuse occlusion of hepatic veins
por: He, Fuliang, et al.
Publicado: (2016)